Evidence map›Paper›PMID 39678331›Full record

ArticleResearch square2024

Albumin orchestrates a natural host defense mechanism against mucormycosis.

Antonis Pikoulas, Ioannis Morianos, Vassilis Nidris Nidris, Rania Hamdy, Angeles López-López, Maria Moran-Garrido, Valliappan Muthu, Maria Halabalaki, Maria Papadovasilaki, Kyrmizi Irene and 24 more

Abstract readPreprint
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

34 authors.

Antonis PikoulasSchool of Medicine, University of Crete.
Ioannis MorianosIMBB, FORTH, Nikolaou Plastira 100 GR-70013, Heraklion, Crete GREECE.
Vassilis Nidris NidrisSchool of Medicine, University of Crete.
Rania HamdyResearch Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.
Angeles López-LópezCentro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, 28660 Boadilla del Monte, Ma.
Maria Moran-GarridoCentro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, 28660 Boadilla del Monte, Ma.
Valliappan MuthuDepartment of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Maria HalabalakiDepartment of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.
Maria PapadovasilakiIMBB, FORTH, Nikolaou Plastira 100 GR-70013, Heraklion, Crete GREECE.
Kyrmizi IreneDepartment of Medicine, University of Crete.
Yiyou GuThe Lundquist Institute for Biomedical Innovation, Harbor-UCLA Medical Center.
Robina AertsDepartment of Hematology, University Hospitals Leuven, Leuven, Belgium.
Toine MercierDepartment of Hematology, University Hospitals Leuven, Leuven, Belgium.
Yuri VanbiervlietDepartment of Hematology, University Hospitals Leuven, Leuven, Belgium.ORCID 0000-0002-6169-1920
Sung-Yeon ChoDepartment of Infectious Diseases, Infection Control and Employee Health, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Amy SpalloneDepartment of Infectious Diseases, Infection Control and Employee Health, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Dimitrios SamonakisSchool of Medicine, University of Crete.ORCID 0000-0003-0418-4620
Efstathios KastritisSchool of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Elias DrakosSchool of Medicine, University of Crete.
Maria TzardiSchool of Medicine, University of Crete and University Hospital.
Aristides EliopoulosSchool of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Konstantina GeorgilaSchool of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Agostinho CarvalhoUniversity of Minho.ORCID 0000-0001-8935-8030
Oliver KurzaiInstitute for Hygiene and Microbiology, University of Würzburg, 97080, Würzburg, Germany.
Shivaprakash RudramurthyDepartment of Medical Microbiology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Fanny LanternierService de Maladies Infectieuses et Tropicales, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Université Paris Cite, France.
Kyriacos PetratosForth Institute of Molcular Biology and Biotechnology.ORCID 0000-0003-0876-1835
Johan MaertensDepartment of Hematology, University Hospitals Leuven, Leuven, Belgium.
Vincent BrunoUniversity of Maryland School of Medicine.
Dimitrios KontoyiannisThe University of Texas MD Anderson Cancer Center.
Coral BarbasCentro de Metabolómica y Bioanálisis (CEMBIO), Universidad San Pablo-CEU.ORCID 0000-0003-4722-491X
Sameh SolimanUniversity of Sharjah.ORCID 0000-0002-7691-615X
Ashraf IbrahimThe Lundquist Institute at Harbor-University of California Los Angeles Medical Center.ORCID 0000-0003-3787-8530
Georgios ChamilosInstitute of Molecular Biology and Biotechnology, FORTH, Hellas.ORCID 0000-0002-7987-4055

Funding

Technology CoreU19AI110820 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI WHITE, OWEN R · 2014 to 2023
$36.5M
Novel Toxins and Receptors in Mucormycosis Pathogenesis and TreatmentR01AI063503 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI IBRAHIM, ASHRAF S. · 2006 to 2025
$7.3M
Project 3P01AI186818 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI DIMITRIOS P KONTOYIANNIS · 2025 to 2026
$6.7M
Therapeutic targeting of growth factor receptors to treat MucormycosisR01AI141360 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BRUNO, VINCENT MICHAEL · 2019 to 2023
$2.5M
NIAID NIH HHS P01 AI186818NIAID NIH HHS R01 AI063503NIAID NIH HHS R01 AI141360NIAID NIH HHS U19 AI110820
6 · The paper itself

Abstract

Mucormycosis is an emerging, life-threatening human infection caused by fungi of the order Mucorales. Metabolic disorders uniquely predispose an ever-expanding group of patients to mucormycosis via poorly understood mechanisms. Therefore, it is highly likely that uncharacterized host metabolic effectors confer protective immunity against mucormycosis. Here, we uncover a master regulatory role of albumin in host defense against Mucorales through the modulation of the fungal pathogenicity program. Our initial studies identified severe hypoalbuminemia as a prominent metabolic abnormality and a biomarker of poor outcome in independent cohorts of mucormycosis patients. Strikingly, we found that purified albumin selectively inhibits Mucorales growth among a range of human pathogens, and albumin-deficient mice display susceptibility specifically to mucormycosis. The antifungal activity of albumin is mediated by the release of bound free fatty acids (FFAs). Importantly, albumin prevents FFA oxidation, which results in loss of their antifungal properties. A high degree of FFA oxidation is found in the sera of patients with mucormycosis. Physiologically, albumin-bound FFAs blocks the expression of the mycotoxin mucoricin and renders Mucorales avirulent in vivo. Overall, we discovered a novel host defense mechanism that directs the pathogen to suppress its growth and the expression of virulence factors in response to unfavorable metabolic cues regulated by albumin. These findings have major implications for the pathogenesis and management of mucormycosis.

Indexed as

AlbuminFree fatty acidsfungihost defenseMucoralesmucoricinmucormycosisRhizopusserum

Identifiers

PMID39678331
PMCPMC11643317

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.